Introduction
============

Liver cancer, mainly hepatocellular carcinoma (HCC), is one of the major causes of cancer mortality worldwide ([@b1-ol-0-0-11423]). A recent international survey estimated that 841,080 new cases of liver cancer and 781,631 liver-cancer-related mortalities occurred worldwide in 2018; notably, during the same period China alone accounted for approximately one-half of the total number of new cases and mortalities ([@b1-ol-0-0-11423]). In China, the prevalence of hepatitis B virus (HBV) infection between 2005 and 2006 was \>7% in the entire population, and \>80% of all cases of primary liver cancer were reportedly caused by chronic HBV infection ([@b2-ol-0-0-11423],[@b3-ol-0-0-11423]).

Owing to the development of various detection techniques, the prognosis for liver cancer has improved considerably; however, the improvement has been limited as liver cancer progresses rapidly and is frequently detected in the intermediate or advanced stage with portal vein tumor thrombus (PVTT) or distant (extrahepatic) metastasis ([@b4-ol-0-0-11423]). Distant metastasis, commonly observed in intermediate to advanced stage HCC, severely worsens the prognosis; consequently, survival in patients with HCC and metastasis is significantly shorter compared with that in patients with HCC without metastasis ([@b5-ol-0-0-11423]--[@b7-ol-0-0-11423]). During progression, liver cancer commonly invades the portal veins to form PVTT; the incidence rate of PVTT is 44.0--62.2% ([@b8-ol-0-0-11423]). Studies have reported that the presence of PVTT is an independent predictor of distant metastasis and promotes distant metastasis of HCC ([@b5-ol-0-0-11423]--[@b7-ol-0-0-11423]). Therefore, the mortality rates in patients with HCC and PVTT are considerably higher compared with those without PVTT. The prognosis is particularly poor in patients with HCC-PVTT and metastasis ([@b9-ol-0-0-11423]). Accurately predicting the metastasis of HCC with PVTT is crucial for improving treatment outcomes and prognosis; however, to the best of our knowledge, studies on HCC with PVTT metastasis prediction are not currently available.

In the present study, independent risk factors for distant metastasis of HCC with PVTT were identified to develop an early risk warning system for distant metastasis. The results of this study may facilitate early prediction and appropriate treatment of distant metastasis of HBV-HCC with PVTT to improve the prognosis of patients with intermediate and advanced HCC.

Materials and methods
=====================

### Patients

Data for 182 patients who had received primary diagnoses of HBV-HCC and PVTT and did not exhibit distant metastasis (non-distant metastasis group), and 81 patients who had received diagnoses of HBV-HCC, PVTT and distant metastasis (distant metastasis group) between January 2012 and December 2014 at Beijing Ditan Hospital, Capital Medical University (Beijing, China), were retrospectively examined. In addition, data for 83 patients who had received primary diagnoses of HBV-HCC and PVTT between January 2015 and June 2015 at the same hospital (validation cohort) were also examined. Patients were included if they were 18--85 years old and had received diagnoses of HBV-HCC and PVTT with vascular invasion. Patients were excluded if they exhibited HBV-HCC and PVTT with hepatitis A, C, D or E virus infection or non-hepatitis virus infection, severe diseases (with functional insufficiency) of vital organs (e.g. the heart, lung, kidney, brain or blood), severe mental illness or metastatic HCC, or had incomplete clinical information. This study was approved by the Ethics Committee of Beijing Ditan Hospital, Capital Medical University. As this study was retrospective, informed consent was not required from the patients.

Diagnosis
---------

### HBV infection

According to the Prevention and Treatment Guidelines of Hepatitis B (Version Year 2000) ([@b5-ol-0-0-11423],[@b10-ol-0-0-11423]), patients with a history of hepatitis B, those who tested positive for hepatitis B surface antigen (HBsAg) for \>6 months, and those who continued to test positive for HBsAg and/or HBV DNA were considered to exhibit a chronic HBV infection.

### Primary HCC

Primary HCC was determined through histological and radiological examination. In accordance with the gold standard, specimens of surgically resected liver-occupying lesions and metastatic lesions were examined histologically. According to the radiological diagnosis standard for HCC ([@b5-ol-0-0-11423]), the patients whose CT images showed vessel intake of contrast agent during the arterial phase, vessel loss during the venous phase and advanced phase, and nodes with a diameter \>2 cm were considered to exhibit HCC based on the results of a single radiological examination. However, if the diameter of the nodes was 1--2 cm, the patients were considered to exhibit HCC only when the results of two radiological examinations were consistent ([@b6-ol-0-0-11423]).

### PVTT

The presence of PVTT was determined by assessing the filling defect of the portal trunk or branch, which was determined using ultrasound B, computed tomography (CT), magnetic resonance imaging (MRI) or digital subtraction angiography (DSA) examination. Ultrasound examination identified abnormal echo filling (including hypoecho, isoecho, hyperecho and mixed echo) in the entire portal vein, widening of the inner diameter of the portal vein or interruption of blood signals. CT examination indicated widened portal veins with uneven inner density and filling defects, and enhanced CT scans revealed tumor thrombus shadows with low density but without enhancement by plain scanning. MRI scans demonstrated a high signal shadow of the portal vein. DSA reports revealed filling defects, total interruption and widening of the portal vein.

### Distant metastasis

Patients with distant metastatic lesions in the lung, lymph nodes, kidney and adrenal gland detected through ultrasound B, CT or MRI examination were considered to exhibit distant metastasis.

### Statistical analysis

Clinical characteristics (including age, sex, tumor multiplicity and thrombus site), blood parameters \[red blood cell (RBC) count, neutrophil to lymphocyte (N/L) ratio, platelet count and platelet/lymphocyte (P/L) ratio\], hepatic and kidney function parameters \[levels of aspartate aminotransferase (AST), γ-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), direct bilirubin and creatinine (Cr), as well as albumin/globulin (A/G) ratio\], the thrombin function parameter prothrombin activity (PTA), the HCC indicator α-fetoprotein (AFP), levels of lactate dehydrogenase (LDH) and C-reactive protein (CRP) were reviewed. Data were analyzed using SPSS 20.0 software (IBM Corp.). Data with a normal distribution are expressed as the mean ± standard deviation and were compared between the metastasis and non-metastasis groups in the modeling cohort using Student\'s t-test. Data with abnormal distributions are expressed as the median ± interquartile range and compared between the two groups by using the rank sum test. Enumeration data are expressed as a frequency, and between-group comparisons were conducted using the χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Variables with P\<0.05 in the aforementioned comparisons and those with high clinical significance in the modeling cohort were included in a multivariate logistic regression analysis. Variables that were significantly associated with distant metastasis were determined, and regression coefficients were calculated. Thus, a prediction model for distant metastasis was developed. The prediction accuracy, specificity, sensitivity, false-positive and false-negative values were determined by receiver operating characteristic (ROC) curve analysis. For each value mentioned above, only a single value instead of the mean ± standard derivation is presented, and statistical comparisons between the data for ROC curves were not performed. To validate this model, the patients from both the modeling and validation cohorts were assessed for the presence or absence of distant metastasis using the aforementioned developed model, which was verified by the clinical data.

Results
=======

### Patient basic characteristics

Data from 263 patients who had received primary diagnoses of HBV-HCC and PVTT (modeling cohort) were retrospectively reviewed for the development of a prediction model for distant metastasis. Among them, 81 patients exhibited distant metastasis (metastasis group), whereas 182 patients did not exhibit distant metastasis (non-metastasis group). In addition, data from 83 patients with HBV-HCC and PVTT (comprising 47 patients without metastasis and 36 patients with metastasis) were reviewed for the independent validation of the developed model ([Fig. 1](#f1-ol-0-0-11423){ref-type="fig"}).

### Establishment of the prediction model of distant metastasis

In the modeling cohort, the metastasis and non-metastasis groups differed significantly in tumor thrombus site, blood platelet count, RBC count, P/L ratio, AST level, A/G ratio, GGT, LDH, ALP, CRP and PTA level (P\<0.05; [Table I](#tI-ol-0-0-11423){ref-type="table"}). Variables with P\<0.2 after univariate analysis were included in the multivariate logistic analysis. Since an increase in the N/L ratio is related to the progression and metastasis of liver cancer ([@b11-ol-0-0-11423]--[@b13-ol-0-0-11423]) and serum AFP level is a biomarker for liver cancer, N/L and AFP with P\>0.05 after univariate analysis were also included in the multivariate analysis. The results demonstrated that N/L ratio ≥2.31, RBC count ≥4.07×10^12^ cells/l, CRP level ≥7.02 mg/l, AST level ≥118.5 U/l and tumor thrombus site at branch were significantly associated with distant metastasis of HBV-HCC and PVTT (P\<0.05; odds ratio \>1.00; [Table II](#tII-ol-0-0-11423){ref-type="table"}).

Regression analysis was conducted to further assess the factors associated with distant metastasis. Regression coefficients were calculated for the analyzed factors ([Table II](#tII-ol-0-0-11423){ref-type="table"}). In addition, based on the aforementioned regression analysis of these association factors, the following formula was proposed to predict distant metastasis: Y = −5.276 + 1.711 × CRP (mg/l) + 1.312 × RBC (×10^12^ cells/l) + 1.192 × N/L + 0.912 × AST (U/l) + 0.553 × tumor thrombus site (branch, assignment of 1). The threshold value was −1.05. To assess the formula for the prediction of distant metastasis, ROC analysis was conducted. An area under the ROC curve (AUC) of 0.731 (95% CI, 0.649--0.776), Youden\'s index of 0.3247, sensitivity of 72.88%, specificity of 59.55%, false-positive value of 40.45% and false-negative value of 27.12% were obtained ([Fig. 2](#f2-ol-0-0-11423){ref-type="fig"}). In addition, the prediction efficacy of the model \[determined using a combination of five factors: N/L ratio, RBC count, tumor thrombus site (branch, assignment of 1), AST level and CRP level\] was higher compared with that of any individual factor. The AUC (representing accuracy) and sensitivity of the model were higher compared with those of the individual factors, although the specificity of the model was lower compared with that of the individual factors ([Table III](#tIII-ol-0-0-11423){ref-type="table"}; [Fig. 2](#f2-ol-0-0-11423){ref-type="fig"}).

### Validation of the prediction model of distant metastasis

To validate the established model, the data of the 83 patients (47 non-metastasis and 36 metastasis patients) with HBV-HCC and PVTT in the validation cohort were reviewed. The results of ROC curve analysis revealed an AUC of 0.695 (95% CI, 0.584--0.791), sensitivity of 65.71%, specificity of 68.75%, false-positive value of 31.25% and false-negative value of 34.29% in the validation cohort ([Table IV](#tIV-ol-0-0-11423){ref-type="table"}; [Fig. 3](#f3-ol-0-0-11423){ref-type="fig"}). At Y≤-1.05, the percentages of patients with metastasis in the model and validation cohorts were 27.10 and 31.40%, respectively, whereas at Y\>-1.05, the percentages of patients with metastasis increased significantly (72.90 and 68.60% in the modeling and validation cohorts, respectively; [Fig. 4](#f4-ol-0-0-11423){ref-type="fig"}).

Discussion
==========

HCC commonly invades portal veins and causes PVTT with an incidence of 44.0--62.2% ([@b2-ol-0-0-11423]). PVTT promotes the metastasis of HCC ([@b14-ol-0-0-11423]). If not treated urgently, patients with HCC with PVTT exhibit a median survival time of only 2.7--4.0 months; in addition, mortality in patients with PVTT is considerably higher compared with that in patients without PVTT ([@b10-ol-0-0-11423],[@b15-ol-0-0-11423],[@b16-ol-0-0-11423]). As PVTT is independently associated with distant metastasis of HCC ([@b5-ol-0-0-11423]--[@b7-ol-0-0-11423]), in patients with HCC with PVTT, concomitant distant metastasis considerably increases the mortality rate, although the presence of PVTT alone also leads to poor prognosis. In addition, several treatment methods have been used to improve prognosis for patients with HCC with PVTT. For example, a recent study involving clinical data from 6,474 patients with HCC with PVTT reported that liver resection treatment significantly improved the median overall survival by 1.77 years compared with non-resection treatments ([@b9-ol-0-0-11423]). In addition, transarterial chemoembolization (TACE) combined with γ-knife treatment improved survival rates in patients with HCC with PVTT ([@b17-ol-0-0-11423]). By contrast, metastasis is not easily treated and remains a major cause of treatment failure. To improve the treatment outcomes and prognosis, predicting distant metastasis of HCC with PVTT is crucial.

Variables such as high pretreatment platelet counts, numerous or large tumors, microvascular invasion, incomplete capsulation and high preoperative AFP are significantly associated with distant metastasis in HCC ([@b18-ol-0-0-11423]--[@b21-ol-0-0-11423]); however, prediction models for the metastasis of HCC with PVTT are not currently available, to the best of our knowledge. In the present study, commonly accessed clinical and biochemical parameters were used to screen the risk factors significantly associated with the distant metastasis of primary HCC with PVTT to establish a convenient early warning system for distant metastasis. The results demonstrated that several biochemical parameters, including N/L ratio ≥2.31, RBC count ≥4.07×10^12^ cells/l, CRP level ≥7.02 mg/l, AST level ≥118.5 U/l and tumor thrombus site at branch, were significantly associated with distant metastasis of primary HCC with PVTT. In addition, based on these results, an early prediction system for distant metastasis was proposed, which may be useful for the timely prevention and treatment of distant metastasis of HBV-HCC with PVTT to prolong survival.

Tumor cells produce erythropoietin, which induces the generation of neutrophils ([@b22-ol-0-0-11423]). Neutrophil generation stimulates active oxygen and cytokines to kill tumor cells; however, it simultaneously inhibits TNF-α production and increases the production of interleukin-1 and endothelial growth factor, which promotes the formation of tumor vessels that results in distant metastasis ([@b23-ol-0-0-11423],[@b24-ol-0-0-11423]). Lymphocytes participate in the tumor immune response and induce apoptosis of tumor cells; thus, they inhibit tumor development and recurrence ([@b25-ol-0-0-11423]). A high N/L ratio indicates that the number of neutrophils is higher compared with that of lymphocytes; a high N/L ratio is considered a prognostic factor for the progression and metastasis of liver cancer ([@b11-ol-0-0-11423]--[@b13-ol-0-0-11423]). In the present study, the N/L ratio was significantly associated with distant metastasis in intermediate to advanced HCC.

Thus far, few studies have addressed the role of RBC count in the prognosis of cancer. A previous study demonstrated that a low preoperative RBC count is an independent risk factor for poor prognosis (overall survival) of primary liver cancer following surgical treatment, which may be explained by the observation that preoperative RBC counts indicate worse Child-Pugh grades in patients, indicating the deterioration of liver function ([@b26-ol-0-0-11423]). The results of the present study demonstrated that high RBC counts (≥4.07×10^12^ cells/l) were independently associated with distant metastasis of HCC with PVTT. Tumor-associated macrophages, which are crucial to the progression and prognosis of cancer ([@b27-ol-0-0-11423]--[@b29-ol-0-0-11423]), arise from the spleen ([@b30-ol-0-0-11423]). Macrophages serve a crucial role in erythropoiesis under pathological conditions ([@b31-ol-0-0-11423]--[@b33-ol-0-0-11423]) and promote tumor growth, at least partially by stimulating tumor stress-induced erythropoiesis in the spleen ([@b33-ol-0-0-11423]). This suggests that a high RBC count may be associated with poor prognosis, which may explain the positive association between high RBC counts and distant metastasis of HCC with PVTT in the present study. The role of RBC count in the prognosis of HCC with PVTT needs additional investigation.

CRP is synthesized in hepatic cells and rapidly released into the plasma in the presence of tissue injury, infection and malignant tumors ([@b34-ol-0-0-11423],[@b35-ol-0-0-11423]). CRP is commonly used as a systemic inflammatory marker and is significantly associated with poor survival or recurrence of HCC ([@b36-ol-0-0-11423],[@b37-ol-0-0-11423]). CRP level has even been considered an independent predictor of recurrence of HCC with PVTT ([@b38-ol-0-0-11423]). In the present study, a high CRP level (≥7.02 mg/l) was an independent risk factor for distant metastasis of HCC with PVTT.

A high AST level is considered to be an independent predictor of poor survival of HCC after treatment ([@b39-ol-0-0-11423],[@b40-ol-0-0-11423]), but a correlation between AST and HCC metastasis has not been reported. In the present study, high AST levels (≥118.5 U/l) were significantly associated with distant metastasis in primary HCC with PVTT.

A previous report demonstrated that in patients with HCC, PVTT in the main trunk or the first branch caused a significantly higher occurrence of intrahepatic metastasis compared with that in other locations ([@b41-ol-0-0-11423]). By contrast, the results of the present study revealed that PVTT in the branch was significantly associated with distant metastasis of HCC with PVTT. Further study is required to verify this result.

Several prediction models for distant metastasis of HCC following treatment are available ([@b9-ol-0-0-11423],[@b42-ol-0-0-11423],[@b43-ol-0-0-11423]); however, to the best of our knowledge, no prediction systems for distant metastasis of HCC with PVTT have been reported thus far. Routine laboratory parameters that are significantly associated with distant metastasis, including N/L ratio ≥2.31, RBC count ≥4.07×10^12^ cells/l, CRP level ≥7.02 mg/l, AST level ≥118.5 U/l and tumor thrombus site at branch, were selected and combined to develop an early risk warning model, Y=−5.276 + 1.711 × CRP (mg/l) + 1.312 × RBC (×10^12^ cells/l) + 1.192 × N/L + 0.912 × AST (U/l) + 0.553 × tumor thrombus site (branch), to predict distant metastasis in patients with HBV-HCC and PVTT. Patients with a high Y value (\>-1.05) had a considerably higher possibility of distant metastasis compared with those with a lower Y value in the modeling and validation cohorts. In subsequent studies with a sufficiently larger number of patients, the Y threshold for the formula may be determined more accurately to achieve a more accurate prediction of distant metastasis of HCC with PVTT. This model may be beneficial for the identification of patients with HCC with PVTT with a high risk of distant metastasis to actively provide target treatment (such as liver resection, TACE, TACE with sorafenib or radiotherapy) to prevent and treat metastasis as early as possible. Early prediction of metastasis in combination with current or future treatment methods for metastasis may considerably improve the treatment outcomes and prognosis of patients with intermediate to advanced HCC. To the best of our knowledge, similar results have not been reported thus far. Of note, all the variables included in the model are easily assessed in the clinic, which suggests that the established model may be clinically practical and convenient.

This study has several limitations. First, this was a retrospective study involving medical records from only a single medical center, which may have caused bias of patient selection and incompleteness of patient clinical information. For example, Child-Pugh scores are usually used to evaluate hepatic function, whereas in the present study, TBIL, ALP and PTA, which similarly reflect hepatic function, were used instead. Crucial factors associated with metastasis or prognosis such as HBV markers (HBsAg titers, HBV DNA levels, testing positive or negative for HBeAg and receipt or non-receipt of HBV treatment), des-γ-carboxy prothrombin, the site (intrahepatic or extrahepatic) of metastasis, HCC treatment history (TACE, transcatheter arterial infusion or chemotherapy) and the time interval between the evaluation of clinical parameters and the diagnosis of distant metastasis were not evaluated in the present study, as complete information for all patients was not available. Consequently, these variables were not included in the analysis. Additionally, the sample size of patients with HCC with PVTT, particularly in the validation cohort, was limited. In addition, diagnosis of HCC with PVTT was only based on clinical imaging diagnosis without gold-standard criteria (such as histological observation), which may have weakened the validation of the established model based on the clinical information of the modeling cohort. A prospective study with a larger sample size conducted at multiple centers and with numerous and comprehensive parameters, including Child-Pugh scores, HBV markers, des-γ-carboxy prothrombin, the site of metastasis, HCC treatment history, the time interval between the evaluation of clinical parameters and the diagnosis of distant metastasis and survival data, is needed to validate the results of the present study.

In conclusion, the present study revealed the risk factors significantly associated with distant metastasis of HBV-HCC and PVTT and established an early risk warning model for distant metastasis. This model may facilitate the early prediction and treatment of distant metastasis of HBV-HCC with PVTT to improve the prognosis of patients.
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![Patients in the modeling and validation cohorts. HBV-HCC, hepatitis B virus-associated primary hepatocellular carcinoma; PVTT, portal vein tumor thrombus.](ol-19-04-3249-g00){#f1-ol-0-0-11423}

![ROC analysis of the established model for distant metastasis in the modeling cohort. The red, dark blue, green, yellow, brown, and gray curves indicate ROC curves of the model, tumor thrombus site, N/L ratio, CRP level, AST level, and RBC count, respectively. The light blue curve indicates the reference line. ROC, receiver operating characteristic; N/L, neutrophil to lymphocyte; CRP, C-reactive protein; AST, aspartate aminotransferase; RBC, red blood cell.](ol-19-04-3249-g01){#f2-ol-0-0-11423}

![ROC analysis of the developed model for distant metastasis in the validation cohort. The blue curve indicates ROC curves of model. The green curve indicates the reference line. ROC, receiver operating characteristic.](ol-19-04-3249-g02){#f3-ol-0-0-11423}

![Prediction of distant metastasis in the modeling and validation cohorts.](ol-19-04-3249-g03){#f4-ol-0-0-11423}

###### 

Comparison between distant and non-distant metastasis groups.

  Variables                                        Non-distant metastasis group (n=182)   Distant metastasis group (n=81)   P-value
  ------------------------------------------------ -------------------------------------- --------------------------------- -----------------------------------------------------
  Age, years                                       55.53±10.16                            54.98±12.17                       0.703
  Sex                                                                                                                       0.702
    Male, n (%)                                    155 (85.2)                             71 (87.7)                         
    Female, n (%)                                  27 (14.8)                              10 (12.3)                         
  Tumor multiplicity (single/multiple)             127/55                                 60/21                             0.478
  Tumor thrombus site                                                                                                       0.013^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
    Branch, n (%)                                  68 (37.4)                              46 (56.8)                         
      Unilateral, n                                66                                     37                                
      Bilateral, n                                 2                                      9                                 
    Trunk, n (%)                                   26 (14.3)                              7 (8.6)                           
    Branch + trunk, n (%)                          88 (48.3)                              28 (34.6)                         
  Blood platelet count (×10^9^ cells/l), M (IQR)   94.30 (70.68--143.38)                  108.75 (78.90--189.90)            0.041^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
  RBC count, ×10^12^ cells/l                                                                                                
    \<4.07, n (%)                                  124 (68.1)                             39 (50.0)                         0.006^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
    ≥4.07, n (%)                                   58 (31.9)                              39 (50.0)                         
  N/L ratio                                                                                                                 
    \<2.31, n (%)                                  47 (25.8)                              14 (17.9)                         0.170
    ≥2.31, n (%)                                   135 (74.2)                             64 (82.1)                         
  P/L ratio                                                                                                                 
    \<3.16, n (%)                                  53 (29.1)                              10 (12.8)                         0.005^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
    ≥3.16, n (%)                                   129 (70.9)                             68 (87.2)                         
  AST (U/l), M (IQR)                               71.10 (42.70--106.60)                  90.60 (54.00--189.40)             0.033^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
  TBIL (µmol/l), M (IQR)                           23.55 (14.15--43.03)                   27.70 (16.20--44.90)              0.287
  A/G ratio                                                                                                                 
    \<1.0, n (%)                                   37 (20.3)                              32 (39.5)                         0.004^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
    ≥1.0, n (%)                                    145 (79.7)                             49 (60.5)                         
  GGT (U/l), M (IQR)                               126.15 (67.40--249.70)                 192.40 (115.70--309.70)           0.003^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
  LDH (U/l), M (IQR)                               196.20 (162.40--232.10)                211.70 (178.10--259.00)           0.020^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
  ALP (U/l), M (IQR)                               131.60 (91.40--187.30)                 163.40 (119.20--245.20)           0.002^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
  Creatinine (µmol/l), M (IQR)                     65.00 (56.00--75.00)                   62.30 (56.00--72.00)              0.386
  AFP, µg/l                                                                                                                 
    \<1,000, n (%)                                 93 (57.1)                              32 (45.7)                         0.112
    ≥1,000, n (%)                                  70 (42.9)                              38 (54.3)                         
  CRP, mg/l                                                                                                                 
    \<7.02, n (%)                                  37 (25.3)                              4 (6.8)                           0.003^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
    ≥7.02, n (%)                                   109 (74.7)                             55 (93.2)                         
  PTA, %                                                                                                                    
    \<62.55, n (%)                                 46 (26.4)                              12 (14.8)                         0.039^[a](#tfn1-ol-0-0-11423){ref-type="table-fn"}^
    ≥62.55 m, n (%)                                128 (73.6)                             69 (85.2)                         

P\<0.05. M, median; IQR, interquartile range; RBC, red blood cells; N/L, neutrophil/lymphocyte; P/L, platelet/lymphocyte; AST, aspartate aminotransferase; TBIL, total bilirubin; A/G, albumin/globulin; GGT, gamma-glutamyl transpeptidase; LDH, lactic dehydrogenase; ALP, alkaline phosphatase; AFP, alpha fetoprotein; CRP, C-reactive protein; PTA, prothrombin activity.

###### 

Multivariate analysis of the factors associated with distant metastasis.

  Variables                              Regression coefficient   Assignment   Odds ratio   95% CI          P-value
  -------------------------------------- ------------------------ ------------ ------------ --------------- -----------------------------------------------------
  P/L ratio                                                                                                 
    \<3.16                                                        0            Normal                       
    ≥3.16                                                         1            2.209        0.479--10.191   0.310
  Blood platelet count, ×10^9^ cells/l                                                                      
    \<108                                                                      Normal                       
    ≥108                                                                       1.525        0.515--4.519    0.447
  N/L ratio                                                                                                 
    \<2.31                                                        0            Normal                       
    ≥2.31                                1.192                    1            3.294        1.104--9.829    0.033^[a](#tfn2-ol-0-0-11423){ref-type="table-fn"}^
  RBC count, ×10^12^ cells/l                                                                                
    \<4.07                                                        0            Normal                       
    ≥4.07                                1.312                    1            3.712        1.677--8.218    0.001^[a](#tfn2-ol-0-0-11423){ref-type="table-fn"}^
  A/G ratio                                                                                                 
    \<1.0                                                                      Normal                       
    ≥1.0                                                                       2.359        0.836--6.658    0.105
  LDH, U/l                                                                                                  
    \<218.6                                                                    Normal                       
    ≥218.6                                                                     0.851        0.358--2.022    0.715
  TBIL, µmol/l                                                                                              
    \<12.9                                                                     Normal                       
    ≥12.9                                                                      1.842        0.666--5.100    0.239
  ALP, U/l                                                                                                  
    \<128.8                                                                    Normal                       
    ≥128.8                                                                     0.405        0.133--1.239    0.113
  CRP, mg/l                                                                                                 
    \<7.02                                                        0            Normal                       
    ≥7.02                                1.711                    1            5.537        1.461--20.991   0.012^[a](#tfn2-ol-0-0-11423){ref-type="table-fn"}^
  AST, U/l                                                                                                  
    \<118.5                                                       0            Normal                       
    ≥118.5                               0.912                    1            2.489        1.109--5.657    0.029^[a](#tfn2-ol-0-0-11423){ref-type="table-fn"}^
  GGT, U/l                                                                                                  
    \<100                                                                      Normal                       
    ≥100                                                                       2.450        0.716--8.384    0.153
  PTA                                                                                                       
    \<63                                                                       Normal                       
    \>63                                                                       2.282        0.759--6.859    0.142
  AFP, µg/l                                                                                                 
    \<1,000                                                                    Normal                       
    ≥1,000                                                                     1.578        0.898--2.771    0.113
  Tumor thrombus site                                                                                       
    Branch                               0.553                    1            1.739        1.152--2.547    0.007^[a](#tfn2-ol-0-0-11423){ref-type="table-fn"}^
    Trunk                                                         2                                         
    Branch + trunk                                                3                                         

P\<0.05. P/L, platelet/lymphocyte; N/L, neutrophil/lymphocyte; RBC, red blood cell; A/G, albumin/globulin; LDH, lactic dehydrogenase; TBIL, total bilirubin; ALP, alkaline phosphatase; CRP, C-reactive protein; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; PTA, prothrombin activity; CI, confidence interval.

###### 

Receiver operating characteristic curve analysis of various individual parameters and the established model in the modeling cohort.

  Parameters            Accuracy (95% CI)      Sensitivity (%)   Specificity (%)   False positive value (1-specificity) (%)   False negative value (1-sensitivity) (%)
  --------------------- ---------------------- ----------------- ----------------- ------------------------------------------ ------------------------------------------
  CRP                   0.592 (0.549--0.686)   33.54             90.24               9.76                                     66.46
  N/L ratio             0.562 (0.483--0.608)   32.16             77.05             22.95                                      67.84
  RBC count             0.602 (0.519--0.642)   40.21             76.07             23.93                                      59.88
  Tumor thrombus site   0.589 (0.522--0.645)   40.35             76.51             23.49                                      59.65
  AST                   0.574 (0.531--0.653)   43.75             74.86             25.14                                      56.25
  Model                 0.731 (0.649--0.776)   72.88             59.55             40.55                                      27.12

N/L, neutrophil/lymphocyte; RBC, red blood cell; CRP, C-reactive protein; AST, aspartate aminotransferase; CI, confidence interval.

###### 

Receiver operating characteristic curve analysis of individual parameters and the established model in the validation cohort.

  Parameters            Accuracy (95% CI)      Sensitivity(%)   Specificity(%)   False positive value (1-specificity) (%)   False negative value (1-sensitivity) (%)
  --------------------- ---------------------- ---------------- ---------------- ------------------------------------------ ------------------------------------------
  CRP                   0.594 (0.481--0.701)   77.14            41.67            58.33                                      22.86
  N/L ratio             0.626 (0.531--0.730)   85.71            39.58            60.42                                      14.29
  RBC count             0.502 (0.390--0.641)   40.00            60.42            39.58                                      60.00
  Tumor thrombus site   0.697 (0.584--0.795)   62.86            75.56            24.44                                      37.14
  AST                   0.544 (0.431--0.654)   94.29            14.58            85.42                                      5.71
  Model                 0.695 (0.584--0.791)   65.71            68.75            31.25                                      34.29

N/L, neutrophil/lymphocyte; RBC, red blood cell; CRP, C-reactive protein; AST, aspartate aminotransferase; CI, confidence interval.

[^1]: Contributed equally
